For statin-intolerant patients, which therapy options are reasonable alternatives?

Enhance your knowledge of antihyperlipidemics and lipid management. Study with multiple choice questions and detailed explanations. Ace your test!

Multiple Choice

For statin-intolerant patients, which therapy options are reasonable alternatives?

When statins can’t be used, lowering LDL-C relies on non-statin therapies that act through different mechanisms, often in combination with lifestyle changes. The most reasonable options are ezetimibe, PCSK9 inhibitors, bempedoic acid, and inclisiran, plus ongoing lifestyle optimization. Ezetimibe works by blocking intestinal cholesterol absorption, giving a modest LDL reduction of about 15–20% and is easy to add to therapy since it’s taken orally. PCSK9 inhibitors are potent LDL reducers, lowering LDL by roughly 50–60% by blocking PCSK9 and increasing LDL receptor availability; they’re especially helpful for high-risk patients or those with familial hypercholesterolemia, though they require injections every few weeks. Bempedoic acid targets hepatic cholesterol synthesis by inhibiting ATP citrate lyase, providing about a 20–25% additional LDL drop and is useful in statin-intolerant patients either alone or with ezetimibe. Inclisiran is a PCSK9 pathway–targeting RNA therapy given as injections every several months, producing about a 50% LDL reduction by reducing PCSK9 production. Lifestyle optimization remains an important adjunct to pharmacotherapy, enhancing overall risk reduction. Fibrate therapy and niacin, when used alone, don’t address LDL as effectively or as consistently in statin-intolerant patients and carry less robust evidence for improving cardiovascular outcomes in this setting, so they’re not preferred standalone alternatives.

When statins can’t be used, lowering LDL-C relies on non-statin therapies that act through different mechanisms, often in combination with lifestyle changes. The most reasonable options are ezetimibe, PCSK9 inhibitors, bempedoic acid, and inclisiran, plus ongoing lifestyle optimization.

Ezetimibe works by blocking intestinal cholesterol absorption, giving a modest LDL reduction of about 15–20% and is easy to add to therapy since it’s taken orally. PCSK9 inhibitors are potent LDL reducers, lowering LDL by roughly 50–60% by blocking PCSK9 and increasing LDL receptor availability; they’re especially helpful for high-risk patients or those with familial hypercholesterolemia, though they require injections every few weeks. Bempedoic acid targets hepatic cholesterol synthesis by inhibiting ATP citrate lyase, providing about a 20–25% additional LDL drop and is useful in statin-intolerant patients either alone or with ezetimibe. Inclisiran is a PCSK9 pathway–targeting RNA therapy given as injections every several months, producing about a 50% LDL reduction by reducing PCSK9 production.

Lifestyle optimization remains an important adjunct to pharmacotherapy, enhancing overall risk reduction.

Fibrate therapy and niacin, when used alone, don’t address LDL as effectively or as consistently in statin-intolerant patients and carry less robust evidence for improving cardiovascular outcomes in this setting, so they’re not preferred standalone alternatives.

More practice questions